CA2968398A1 - Pneumolysin mutants and methods of use thereof - Google Patents

Pneumolysin mutants and methods of use thereof Download PDF

Info

Publication number
CA2968398A1
CA2968398A1 CA2968398A CA2968398A CA2968398A1 CA 2968398 A1 CA2968398 A1 CA 2968398A1 CA 2968398 A CA2968398 A CA 2968398A CA 2968398 A CA2968398 A CA 2968398A CA 2968398 A1 CA2968398 A1 CA 2968398A1
Authority
CA
Canada
Prior art keywords
amino acid
polypeptide
mutant pneumolysin
pneumolysin polypeptide
purified mutant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA2968398A
Other languages
English (en)
French (fr)
Inventor
Rodney K. Tweten
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Oklahoma
Original Assignee
University of Oklahoma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Oklahoma filed Critical University of Oklahoma
Publication of CA2968398A1 publication Critical patent/CA2968398A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • C07K14/3156—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci from Streptococcus pneumoniae (Pneumococcus)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
CA2968398A 2014-11-21 2015-11-20 Pneumolysin mutants and methods of use thereof Pending CA2968398A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462082848P 2014-11-21 2014-11-21
US62/082,848 2014-11-21
PCT/US2015/061859 WO2016081839A1 (en) 2014-11-21 2015-11-20 Pneumolysin mutants and methods of use thereof

Publications (1)

Publication Number Publication Date
CA2968398A1 true CA2968398A1 (en) 2016-05-26

Family

ID=56014598

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2968398A Pending CA2968398A1 (en) 2014-11-21 2015-11-20 Pneumolysin mutants and methods of use thereof

Country Status (21)

Country Link
US (1) US10562941B2 (enExample)
EP (2) EP4501949A3 (enExample)
JP (1) JP6734274B2 (enExample)
KR (1) KR102304828B1 (enExample)
CN (1) CN107106635B (enExample)
AU (1) AU2015349787B2 (enExample)
CA (1) CA2968398A1 (enExample)
DK (1) DK3220937T3 (enExample)
ES (1) ES2993430T3 (enExample)
FI (1) FI3220937T3 (enExample)
HR (1) HRP20241627T1 (enExample)
HU (1) HUE069200T2 (enExample)
LT (1) LT3220937T (enExample)
MX (1) MX381872B (enExample)
PL (1) PL3220937T3 (enExample)
PT (1) PT3220937T (enExample)
RS (1) RS66221B1 (enExample)
SI (1) SI3220937T1 (enExample)
SM (1) SMT202400482T1 (enExample)
WO (1) WO2016081839A1 (enExample)
ZA (1) ZA201703881B (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012134975A1 (en) 2011-03-28 2012-10-04 St. Jude Children's Research Hospital Methods and compositions employing immunogenic fusion proteins
US11844829B2 (en) 2016-12-28 2023-12-19 Zalvac Ab Microparticles from Streptococcus pneumoniae as vaccine antigens
CN110967482B (zh) * 2018-09-30 2023-04-07 重庆市畜牧科学院 一种山羊化脓隐秘杆菌感染检测试剂盒及其检测方法
CN113264999B (zh) * 2021-04-29 2023-02-28 星济生物(苏州)有限公司 中和肺炎链球菌溶血素蛋白的抗原结合蛋白及其用途
WO2023039223A1 (en) * 2021-09-09 2023-03-16 Affinivax, Inc. Multivalent pneumococcal vaccines
WO2023092090A1 (en) 2021-11-18 2023-05-25 Matrivax, Inc. Immunogenic fusion protein compositions and methods of use thereof
CN115927420A (zh) * 2022-05-27 2023-04-07 贵州省畜牧兽医研究所 一种溶血素重组表达及间接elisa检测方法及应用

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4686102A (en) 1984-04-12 1987-08-11 American Cyanamid Company Multivalent pneumococcal vaccine and preparation thereof
HUT58804A (en) 1988-12-16 1992-03-30 James Cleland Paton Process for producing pneumolysine mutants and pneumococcus vaccines
US6716432B1 (en) 1988-12-16 2004-04-06 James Cleland Paton Pneumolysin mutants and pneumococcal vaccines made therefrom
US5854416A (en) 1991-11-14 1998-12-29 The United States Of America As Represented By The Department Of Health And Human Services Streptococcus pneumoniae 37-KDA surface adhesin a protein and nucleic acids coding therefor
US5565204A (en) 1994-08-24 1996-10-15 American Cyanamid Company Pneumococcal polysaccharide-recombinant pneumolysin conjugate vaccines for immunization against pneumococcal infections
CA2221480A1 (en) 1995-06-07 1996-12-19 The Regents Of The University Of Minnesota Mutants of streptococcal toxin a and methods of use
JP2001510031A (ja) 1997-07-21 2001-07-31 ノース・アメリカン・ヴァクシン・インコーポレーテッド ワクチンとしての修飾された免疫原ニューモリシン組成物
US6224880B1 (en) 1997-09-24 2001-05-01 Merck & Co., Inc. Immunization against Streptococcus pneumoniae using conjugated and unconjugated pneumoccocal polysaccharide vaccines
US6903184B1 (en) 1998-03-02 2005-06-07 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Multiple antigenic peptides immunogenic against Streptococcus pneumonia
PL204863B1 (pl) 1998-07-22 2010-02-26 Stichting Dienst Landbouwkundi Zastosowanie mutanta Streptococcus, szczepionka i sposoby kontrolowania lub eliminowania choroby paciorkowcowej w populacji
DK1140157T3 (da) 1998-12-21 2009-06-08 Medimmune Inc Streptococcus pneumoniae-proteiner og immunogene fragmenter til vacciner
US6887480B1 (en) 1999-06-10 2005-05-03 Medimmune, Inc. Streptococcus pneumoniae proteins and vaccines
AU2002351623A1 (en) 2001-12-20 2003-07-09 Shire Biochem Inc. Streptococcus antigens
US7217791B2 (en) 2002-11-07 2007-05-15 Synergy America, Inc. Compositions and methods for treating or preventing pneumococcal infection
WO2005076696A2 (en) 2004-02-13 2005-08-25 Sanofi Pasteur Limited Pneumolysin derivatives
GB0410220D0 (en) * 2004-05-07 2004-06-09 Kirkham Lea Ann Mutant pneumolysin proteins
WO2005108419A1 (en) 2004-05-07 2005-11-17 Lea-Ann Kirkham Mutant cholesterol-binding cytolysin proteins
US9370557B2 (en) 2006-06-15 2016-06-21 The University Court Of The University Of Glasgow Adjuvant compounds
US8128939B2 (en) * 2007-04-13 2012-03-06 The Board Of Regents Of The University Of Oklahoma Mutants of cholesterol-dependent cytolysins and uses thereof
BRPI0923649A2 (pt) 2008-12-24 2016-01-19 Netherlands Vaccine Inst polipeptídeos de pneumolisina (ply) de streptococcus pneumoniae modificados.
CA2784447A1 (en) * 2009-12-22 2011-06-30 Sanofi Pasteur Limited Adjuvanted immunogenic compositions and related methods
CL2010001216A1 (es) * 2010-11-08 2011-01-28 New Tech Copper S P A Sistema para confinar el espacio sobre el electrolito en una celda de electro obtencion y evacuar los aerosoles generados, que comprende un confinador insertado en cada anodo, con un par de proyecciones flexibles y un par de perfiles en angulo, y ductos longitudinales con perforaciones sobre el nivel del electrolito.
WO2012134975A1 (en) * 2011-03-28 2012-10-04 St. Jude Children's Research Hospital Methods and compositions employing immunogenic fusion proteins
JP6397805B2 (ja) 2015-08-28 2018-09-26 東芝メモリ株式会社 半導体製造装置およびその運転方法

Also Published As

Publication number Publication date
US10562941B2 (en) 2020-02-18
DK3220937T3 (da) 2024-12-02
WO2016081839A1 (en) 2016-05-26
PL3220937T3 (pl) 2025-01-27
CN107106635B (zh) 2021-10-08
EP3220937B1 (en) 2024-09-04
HUE069200T2 (hu) 2025-02-28
PT3220937T (pt) 2024-11-18
EP3220937A1 (en) 2017-09-27
SMT202400482T1 (it) 2025-01-14
KR102304828B1 (ko) 2021-09-27
AU2015349787B2 (en) 2021-07-29
LT3220937T (lt) 2024-12-27
ES2993430T3 (en) 2024-12-30
FI3220937T3 (fi) 2024-11-29
EP4501949A2 (en) 2025-02-05
KR20170083635A (ko) 2017-07-18
SI3220937T1 (sl) 2025-03-31
MX381872B (es) 2025-03-13
BR112017010696A2 (pt) 2017-12-26
AU2015349787A1 (en) 2017-06-22
RS66221B1 (sr) 2024-12-31
JP6734274B2 (ja) 2020-08-05
JP2017536124A (ja) 2017-12-07
US20180312552A1 (en) 2018-11-01
CN107106635A (zh) 2017-08-29
MX2017006625A (es) 2018-01-15
HRP20241627T1 (hr) 2025-02-14
EP4501949A3 (en) 2025-04-30
ZA201703881B (en) 2021-10-27
EP3220937A4 (en) 2018-05-30

Similar Documents

Publication Publication Date Title
US8128939B2 (en) Mutants of cholesterol-dependent cytolysins and uses thereof
EP3220937B1 (en) Pneumolysin mutants and methods of use thereof
US6582706B1 (en) Vaccine compositions comprising Streptococcus pneumoniae polypeptides having selected structural MOTIFS
KR100891398B1 (ko) 신규한 스트렙토코커스 항원
AU777856B2 (en) Streptococcus pneumoniae proteins and vaccines
US6833356B1 (en) Pneumococcal protein homologs and fragments for vaccines
JP2001505439A (ja) 変異体レンサ球菌毒素ａおよび使用法
US6887480B1 (en) Streptococcus pneumoniae proteins and vaccines
JP4749641B2 (ja) ワクチン用の肺炎球菌タンパク質の相同体および断片
HK1237274B (en) Pneumolysin mutants and methods of use thereof
HK1237274A1 (en) Pneumolysin mutants and methods of use thereof
BR112017010696B1 (pt) Polipeptídeo de pneumolisina mutante purificada, composição imunogênica, métodos de preparo da dita composição imunogênica e uso do dito polipeptídeo para tratar, prevenir profilaticamente ou reduzir a ocorrência de uma condição, doença ou infecção causada por streptococcus pneumoniae

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20201118

EEER Examination request

Effective date: 20201118

EEER Examination request

Effective date: 20201118

EEER Examination request

Effective date: 20201118

EEER Examination request

Effective date: 20201118

EEER Examination request

Effective date: 20201118

EEER Examination request

Effective date: 20201118

EEER Examination request

Effective date: 20201118

EEER Examination request

Effective date: 20201118

EEER Examination request

Effective date: 20201118